Literature DB >> 19562298

C5a-induced in vitro basophil activation in patients with chronic urticaria: a pilot study.

Peter Korosec1, Tjasa Subic, Katja Adamic, Mira Silar, Mitja Kosnik.   

Abstract

BACKGROUND: Complement component 5a (C5a) might be involved in the formation of wheals in patients with chronic urticaria (CU). We sought to compare the in vitro responsiveness of basophils to C5a in patients with CU and in a control group.
METHODS: Basophil surface expression of activation marker CD63 induced by C5a, anti-FcepsilonRI mAb or anti-IgE pAb was measured using flow cytometry in 17 patients with CU and in 10 healthy controls.
RESULTS: Patients with CU showed significantly greater basophil CD63 surface expression induced by C5a (median [interquartile range]; 16.4% [13-25.1]; P = 0.011) than the group of healthy controls (10.7% [7.2-16.8]). In contrast, basophil CD63 response to anti-IgE and anti-FcepsilonRI was lower in the CU group (12.3% [6-36.3]; 25.9% [12.5-60.5]) than in the control group (51.7% [6.7-84.3]; 62.1% [9.7-89.2]), although not statistically significant.
CONCLUSION: Results of this pilot study suggest that patients with CU might have an enhanced basophil response to stimulation with C5a, indicating that further studies in CU basophil responsiveness are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562298     DOI: 10.1007/s00508-009-1168-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  25 in total

1.  Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria.

Authors:  Riccardo Asero
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

2.  Dual phase priming by IL-3 for leukotriene C4 generation in human basophils: difference in characteristics between acute and late priming effects.

Authors:  K Miura; D W MacGlashan
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

3.  Basophilic leucopenia in different forms of urticaria.

Authors:  H RORSMAN
Journal:  Acta Allergol       Date:  1962

4.  Monitoring human basophil activation via CD63 monoclonal antibody 435.

Authors:  E F Knol; F P Mul; H Jansen; J Calafat; D Roos
Journal:  J Allergy Clin Immunol       Date:  1991-09       Impact factor: 10.793

5.  Differential mediator release from basophils of allergic and non-allergic asthmatic patients after stimulation with anti-IgE and C5a.

Authors:  O Abrahamsen; H Haas; J Schreiber; M Schlaak
Journal:  Clin Exp Allergy       Date:  2001-03       Impact factor: 5.018

6.  Complement dependence of histamine release in chronic urticaria.

Authors:  M Ferrer; K Nakazawa; A P Kaplan
Journal:  J Allergy Clin Immunol       Date:  1999-07       Impact factor: 10.793

7.  Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria.

Authors:  A M Marsland; S Soundararajan; K Joseph; A P Kaplan
Journal:  Clin Exp Allergy       Date:  2005-05       Impact factor: 5.018

8.  Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria.

Authors:  R A Sabroe; D M Francis; R M Barr; A K Black; M W Greaves
Journal:  J Allergy Clin Immunol       Date:  1998-10       Impact factor: 10.793

9.  Prevalence of Helicobacter pylori-associated gastritis in chronic urticaria.

Authors:  B Wedi; S Wagner; T Werfel; M P Manns; A Kapp
Journal:  Int Arch Allergy Immunol       Date:  1998-08       Impact factor: 2.749

10.  Release of sulfidoleukotrienes in vitro: its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid.

Authors:  W Czech; E Schöpf; A Kapp
Journal:  Inflamm Res       Date:  1995-07       Impact factor: 4.575

View more
  3 in total

1.  COPD is not COPD is not allergy.

Authors:  Stanislav Suskovic
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 2.  Basophils and allergic inflammation.

Authors:  Mark C Siracusa; Brian S Kim; Jonathan M Spergel; David Artis
Journal:  J Allergy Clin Immunol       Date:  2013-10       Impact factor: 10.793

Review 3.  Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

Authors:  Ana M Giménez-Arnau; Andaç Salman
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.